Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 5/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971453 | 1.00 | TNKS (0.52) | TNKSTNKS2PGRMAPK14CYP1A2 | |
| SCHEMBL4719167 | 0.98 | TNKS (0.51) | TNKSTNKS2PGRMAPK14CYP1A2 | |
| SCHEMBL29622048 | 0.97 | TNKS (0.52) | TNKSTNKS2PGRMAPK14CYP1A2 | |
| SCHEMBL19838281 | 0.97 | TNKS (0.52) | TNKSTNKS2PGRMAPK14CYP1A2 | |
| SCHEMBL16858420 | 0.93 | TNKS (0.51) | TNKSTNKS2PGRMAPK14CYP1A2 | |
| SCHEMBL29860095 | 0.93 | TNKS (0.51) | TNKSTNKS2PGRMAPK14CYP1A2 | |
| SCHEMBL23778308 | 0.87 | TNKS (0.50) | TNKSTNKS2PGRMAPK14CYP1A2 | |
| SCHEMBL20955239 | 0.87 | NR3C2 (0.52) | TNKSTNKS2PGRMAPK14CYP1A2 | |
| SCHEMBL25399999 | 0.86 | PGR (0.58) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL29609794 | 0.86 | PGR (0.58) | PGRCYP1A2MAPTCYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116546990-B | CD73 inhibitor and pharmaceutical application thereof | RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-114539340-B | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-4251633-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-116546990-A | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022109741-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | TNKS 222/4885TNKS2 354/4885PGR 2202/4885 |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | TNKS 222/4885TNKS2 354/4885PGR 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.